Evidence map›Paper›PMID 34861509›Full record

ReviewTransplantation reviews (Orlando, Fla.)2022

Interleukin-27 in liver xenotransplantation: A rational target to mitigate ischemia reperfusion injury and increase xenograft survival.

Rudy Matheson, Kevin Deng, Guoli Huai, Kang Mi Lee, Noel Feeney, Taylor M Coe, Daniel Cloonan, Nikolaos Serifis, Qiang Fu, Simon C Robson and 2 more

Open access · hybridAbstract readReview
In one paragraph

Review in Transplantation reviews (Orlando, Fla.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Rudy MathesonCenter for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, United States. Electronic address: rmatheson@mgh.harvard.edu.
Kevin DengCenter for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, United States.
Guoli HuaiCenter for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, United States; Organ Transplantation Center, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Kang Mi LeeCenter for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, United States.
Noel FeeneyCenter for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, United States.
Taylor M CoeCenter for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, United States.
Daniel CloonanCenter for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, United States.
Nikolaos SerifisCenter for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, United States.
Qiang FuCenter for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, United States; Organ Transplantation Center, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Simon C RobsonBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
James F MarkmannCenter for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, United States.
Christian LeGuernCenter for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, United States.
Massachusetts General Hospital · USBeth Israel Deaconess Medical Center · US

Funding

TRAINING IN TRANSPLANTATION BIOLOGYT32AI007529 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MADSEN, JOREN C · 1998 to 2024
$6.4M
Liver Xenotransplantation using CRISPR-modified Porcine OrgansR01AI146248 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MARKMANN, JAMES FRANCIS · 2020 to 2020
$772k
NIAID NIH HHS R01 AI146248NIAID NIH HHS T32 AI007529
6 · The paper itself

Abstract

Transplantation of xenogeneic organs is an attractive solution to the existing organ shortage dilemma, thus, securing a clinically acceptable prolongation of xenograft survival is an important goal. In preclinical transplantation models, recipients of liver, kidney, heart, or lung xenotransplants demonstrate significant graft damages through the release of pro-inflammatory molecules, including the C-reactive protein, cytokines, and histone-DNA complexes that all foster graft rejection. Recent studies have demonstrated that mitigation of ischemia reperfusion injury (IRI) greatly improves xenograft survival. Organ IRI develops primarily on a complex network of cytokines and chemokines responding to molecular cues from the graft milieu. Among these, interleukin 27 (IL-27) plays an immunomodulatory role in IRI onset due to graft environment-dependent pro- and anti- inflammatory activities. This review focuses on the impact of IL-27 on IRI of liver xenotransplants and provides insights on the function of IL-27 that could potentially guide genetic engineering strategies of donor pigs and/or conditioning of organs prior to transplantation.

Indexed as

Interleukin-27Liver TransplantationReperfusion InjuryAnimalsHeterograftsHumansSwineTransplantation, HeterologousInterleukin-27IL-27/CD39 axisIschemia re-perfusion injuryLiver xeno-transplantationPro- and anti-inflammatory cytokine interaction

Identifiers

PMID34861509
PMCPMC10072133
OpenAlexW3215492823

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.